Aggregated from the cited literature below. We summarize sources — we don't author claims.
Survodutide (aliases 2805997-46-8, BI-456906, GLXC-27923) is described in the provided sources as a dual agonist of glucagon and GLP-1 receptors, investigated in clinical trials for conditions including metabolic dysfunction-associated steatohepatitis (MASH)/liver fibrosis, obesity, and type 2 diabetes, and discussed in relation to GLP-1-based therapies and additional investigational indications.
Mechanism (as reported)
A study described survodutide as a dual agonist of glucagon receptor and GLP-1 receptor, with dual agonism proposed as potentially more effective than GLP-1 receptor agonism alone for metabolic dysfunction-associated steatohepatitis (MASH). (PMID 38847460)
Key findings (each cites a source)
A review reported that investigational molecules such as survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. (PMID 38843460) [PMID 38843460]
A phase 2 randomized trial in adults with biopsy-confirmed MASH and fibrosis stages F1 through F3 reported that histologic improvement in MASH with no worsening of fibrosis occurred in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) versus 14% with placebo, with a significant quadratic dose-response (P<0.001). (PMID 38847460) [PMID 38847460]
In the same phase 2 MASH trial, a ≥30% decrease in liver fat content occurred in 63% (2.4 mg), 67% (4.8 mg), and 57% (6.0 mg) versus 14% with placebo, and ≥1-stage fibrosis improvement occurred in 34%, 36%, 34%, and 22% respectively. (PMID 38847460) [PMID 38847460]
In the phase 2 MASH trial, adverse events more frequent with survodutide than placebo included nausea (66% vs 23%), diarrhea (49% vs 23%), and vomiting (41% vs 4%), and serious adverse events occurred in 8% with survodutide and 7% with placebo. (PMID 38847460) [PMID 38847460]
A phase 2 obesity dose-finding trial reported mean bodyweight reductions from baseline to week 46 of -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), and -14.9% (4.8 mg) versus -2.8% with placebo (planned treatment analysis). (PMID 38330987) [PMID 38330987]
In the obesity dose-finding phase 2 trial, adverse events occurred in 91% of survodutide recipients versus 75% of placebo recipients, and were primarily gastrointestinal (75% of survodutide recipients vs 42% of placebo recipients). (PMID 38330987) [PMID 38330987]
A phase I pharmacokinetic and safety study in cirrhosis reported that mean AUC0-∞ and Cmax were similar in participants with cirrhosis compared with healthy individuals (adjusted geometric mean ratios with confidence intervals spanning 1) after a single-dose cohort, and reported drug-related treatment-emergent adverse events rates across healthy and cirrhosis groups. (PMID 38857788) [PMID 38857788]
In the cirrhosis phase I study, liver fat content, liver stiffness, liver volume, body weight, and other hepatic and metabolic disease markers were generally reduced after 28 weeks of survodutide treatment, and the study concluded that survodutide was generally tolerable in compensated or decompensated cirrhosis and did not require pharmacokinetic-related dose adjustment. (PMID 38857788) [PMID 38857788]
In a phase II randomized trial in type 2 diabetes, the primary endpoint reported was absolute change in HbA1c at 16 weeks, and the study reported that adjusted mean HbA1c decreased from baseline across survodutide dose groups, with dose-related effects also described for bodyweight. (PMID 38095657) [PMID 38095657]
In the type 2 diabetes phase II trial, adverse events were reported for 77.8% of survodutide-treated participants and were mainly gastrointestinal, compared with 52.5% receiving placebo and 52.0% receiving semaglutide. (PMID 38095657) [PMID 38095657]
A review on obesity pharmacotherapies reported that there are ongoing phase 3 trials on GLP-1/glucagon receptor dual agonists including survodutide. (PMID 39952695) [PMID 39952695]
A trial design/rationale paper reported that SYNCHRONIZE-CVOT is a phase 3 randomized, double-blind, parallel-group, event-driven cardiovascular outcomes study of survodutide in adults with obesity and increased cardiovascular risk, with a primary endpoint of time to first occurrence of a composite 5-point major adverse cardiovascular events outcome. (PMID 39453356) [PMID 39453356]
Vendor test rankings (7)
Vendors ranked by their independent third-party test grade for Survodutide, attributed to Finnrick. The grade is their verdict, not ours.
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.6% across 33 tests. Not our verdict.
Labs: freedomdiagnosticstesting.com, Vanguard Laboratory, Bioviridian, Janoshik Labs, BioRegen, SR Bio Labs, Chromate, Trust Pointe Analytics.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E · The New England journal of medicine · 2024 · PMID 38847460
FAQ
What is Survodutide?
Survodutide (2805997-46-8, BI-456906, GLXC-27923) is classified under glp-1 & incretin agonists, currently studied in clinical trials. Research goals associated with it include metabolic & weight.
Is Survodutide FDA-approved?
Not yet — Survodutide is investigational and currently in clinical trials.
What does the research on Survodutide say?
peptideone aggregates 10 references from PubMed for Survodutide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.